Lisa Catalli
Nurse Practitioner 3
Medicine
Chancellor/EVC/FAS

Awards

Show all (2) Hide

• Advanced Transplant Provider Research Grant, American Society of Transplant Surgeons, 2021-2022
• Health Team PRIDE Award; HCV Project ECHO, UCSF Medical Center, 2019-2020

Education & Training

Show all (2) Hide

• MSN Nurse Practitioner UCSF School of Nursing 1995
• BA Human Development CSULB 1989

Interests

Show all (2) Hide

• Viral Hepatitis
• Non-Alcoholic Fatty Liver Disease

Publications (5)

Top publication keywords:
Interferon-alphaRibavirinProtease InhibitorsPrimary Health CareSustained Virologic ResponseOligopeptidesPhysiciansAntiviral AgentsHepacivirusLiver CirrhosisHepatitis C, ChronicProlineElasticity Imaging TechniquesLiverHepatitis C

• Staff-Facilitated Telemedicine Care Delivery for Treatment of Hepatitis C Infection among People Who Inject Drugs.
  Healthcare (Basel, Switzerland) 2024 Kim RG, McDonell C, McKinney J, Catalli L, Price JC, Morris MD
• Strategies to increase primary care provider capacity for hepatitis C care: The California ECHO-PLUS study.
  Journal of viral hepatitis 2023 Terrault NA, Slepin J, Kanner R, Gailloux K, Catalli L, McKinney J, Straley S, Morris P, Hluhanich R, Gonzalez-Flores A, Dodge J, Sarkar S
• Post-sustained Virologic Response Liver Stiffness May Underestimate Fibrosis After Direct Acting Antiviral-containing Therapy.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Kardashian A, McKinney J, Huynh N, Yu R, Peters M, Catalli L, Price JC
• Novel NS5B Resistance-Associated Substitution Emerges Under Failing Sofosbuvir/Ledipasvir Therapy.
  Clinical liver disease 2019 Catalli L, Martens SK, Terrault NA, Reeves JD
• Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
  Alimentary pharmacology & therapeutics 2014 Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA